The bill amends the "Benefit Determination and Utilization Review Act" by adding a new section that prohibits healthcare insurers from requiring or conducting a prospective or concurrent review for certain prescription medications used in the treatment of alcohol or opioid use disorders. Specifically, this includes medications that contain Methadone, Buprenorphine, or Naltrexone, as well as those that were approved by the FDA for the mitigation of opioid withdrawal symptoms, for health benefit plans issued or renewed on or after the effective date of this section.

Additionally, the bill introduces a new section to the "Medical Assistance" chapter, which mandates that each Medicaid managed care organization utilize the medical necessity criteria selected by the executive office of health and human services when conducting utilization reviews for Medicaid benefits. This act is set to take effect upon passage.